Peptidyl-prolyl Cis/Trans Isomerase NIMA-interacting 1 Associates with Insulin Receptor Substrate-1 and Enhances Insulin Actions and Adipogenesis

Received for publication, November 29, 2010, and in revised form, February 16, 2011 Published, JBC Papers in Press, March 17, 2011, DOI 10.1074/jbc.M110.206904

Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (Pin1) is a unique enzyme that associates with the pSer/Thr-Pro motif and catalyzes cis-trans isomerization. We identified Pin1 in the immunoprecipitates of overexpressed IRS-1 with myc and FLAG tags in mouse livers and confirmed the association between IRS-1 and Pin1 by not only overexpression experiments but also endogenously in the mouse liver. The analysis using deletion- and point-mutated Pin1 and IRS-1 constructs revealed the WW domain located in the N terminus of Pin1 and Ser-434 in the SAIN (Shc and IRS-1 NPXY binding) domain of IRS-1 to be involved in their association. Subsequently, we investigated the role of Pin1 in IRS-1 mediated insulin signaling. The overexpression of Pin1 in HepG2 cells markedly enhanced insulin-induced IRS-1 phosphorylation and its downstream events: phosphatidylinositol 3-kinase binding with IRS-1 and Akt phosphorylation. In contrast, the treatment of HepG2 cells with Pin1 siRNA or the Pin1 inhibitor Juglone suppressed these events. In good agreement with these in vitro data, Pin1 knock-out mice exhibited impaired insulin signaling with glucose intolerance, whereas adenosine gene transfer of Pin1 into the ob/ob mouse liver mostly normalized insulin signaling and restored glucose tolerance. In addition, it was also demonstrated that Pin1 plays a critical role in adipose differentiation, making Pin1 knock-out mice resistant to diet-induced obesity. Importantly, Pin1 expression was shown to be up-regulated in accordantly but only by producing conformational changes (1–4). Pin1, one of the peptidyl-prolyl cis/trans isomerase isoforms that is distinct from the two major classes of isomerases, the cyclophilins and the FK506-binding proteins (5, 6), was initially cloned as a NIMA kinase interacting protein (7) and specifically recognizes a proline bond preceded by a phosphorylated serine or threonine residue (phospho-Ser/Thr-Pro motif) with a WW domain at its N terminus (8, 9). Then, its C-terminal PPIase domain was shown to catalyze cis-trans isomerization of the target peptidyl-prolyl bonds and thereby modify the actions of target proteins (8, 9). Since its discovery, numerous proteins have been identified as Pin1 substrates (8, 10), implicating it in the regulation of many biological processes. For example, Pin1 inhibits the phosphorylation of Cdc25 and controls the replication checkpoint in the cell cycle (11, 12). Pin1 also stabilizes the tumor suppressor p53 and is abundantly expressed in some malignant tumors, suggesting involvement in malignant transformation (13, 14). On the other hand, Pin1 is also expressed at high levels in most neurons (15, 16). Although much remains to be clarified regarding the role of Pin1 in neurons, it reportedly protects against neurodegeneration via several independent mechanisms (15, 16), as supported by the fact that Pin1 knock-out (KO) mice exhibit abnormal central nervous function (15, 16). In addition, the enzymatic function of Pin1 is reportedly inactivated by oxidative stress modification occurring in the early stages of Alzheimer disease, implicating Pin1 in brain function (16, 17). Therefore, Pin1 has been implicated in the pathogenesis of two major disorders; cancer and Alzheimer disease (9, 10).

Very recently, we reported that Pin1 expression is higher in the fed than in the fasted state and that Pin1 associates with CRTC2, a co-activator of CRE (cAMP-response element-binding protein), and suppresses CRE (cAMP-response ele-
Pin1 Enhances Insulin Actions and Adipogenesis

EXPERIMENTAL PROCEDURES

Materials—Affinity-purified antibodies against IRS-1, IRS-2, phosphorylated tyrosine (4G10), and Akt/protein kinase B were prepared as previously described (19). Anti-Pin1 antibody was generated by immunizing rabbits with the peptide QMQKPFE-DASFATRGTGEMSPFVFTDSDGIHITRTE (amino acids 129–163 of human Pin1). Anti-FLAG tag antibody was purchased from Sigma, and antibodies against the p85 subunit of phosphotyrosinol 3-kinase, phospho-Ser-473 and phospho-Thr-328 of Akt, and anti-actin were from Cell Signaling Technology (Danvers, MA).

Cell Culture—Sf9 cells were grown in TC100 (Invitrogen) medium containing 10% fetal bovine serum (FBS) at 27 °C. HepG2 hepatoma cells and human preadipocyte were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FBS at 37 °C in 5% (v/v) CO2 in air. Mouse 3T3-L1 fibroblasts were maintained in DMEM containing 10% donor calf serum and lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% (w/v) glycerol, 10 mM MgCl2, 10 mM EGTA, 1 mM Na3VO4, 1% (w/v) Triton X-100, 5 mM ZnCl2, 2 mM PMSF, 10 µg/ml aprotinin, and 1 µg/ml leupeptin). Lysates were centrifuged at 100,000 × g for 20 min at 4 °C. Supernatants were passed through a 5-μm filter, incubated with 150 µl of Sepharose beads for 60 min at 4 °C, and then passed through a 0.65-μm filter. The filtrated supernatant was mixed with 150 µl of anti-myc-conjugated Sepharose beads for the first immunoprecipitation. After incubation for 90 min at 4 °C, the beads were washed 5 times with 1.5 ml of TNT buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% (w/v) glycerol, and 0.1% (w/v) Triton X-100), twice with buffer A (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.1% (w/v) Triton X-100), and finally once with TNT buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.1% (w/v) Triton X-100). The washed beads were incubated with 15 units of tobacco etch virus protease (Invitrogen) in 150 µl of TNT buffer to release bound materials from the beads. After incubation for 60 min at room temperature, supernatants were pooled, and the beads were washed twice with 75 µl of buffer A. The resulting supernatants were combined and incubated with 25 µl of FLAG-Sepharose beads for the second immunoprecipitation. After a 60-min incubation at room temperature, the beads were washed 3 times with 500 µl of buffer A, and proteins bound to the FLAG beads were dissociated by incubation with 1 mM synthetic FLAG peptides in buffer A for 120 min at 4 °C. Approximately 3 µg of protein (0.01% of starting materials) were routinely recovered by this procedure. The samples were electrophoresed and subjected to SDS-PAGE and immunoblotting.

Immunoprecipitation and Immunoblotting—The cells were solubilized with Laemmli buffer (0.2 M Tris-HCl, 4% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.1% bromphenol blue). Equal amounts of protein from whole cell lysates were resolved by SDS-PAGE. Then the proteins were transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA) using an electroblotting apparatus (Mighty Small
Transphor; Amersham Biosciences) and subjected to immunoblotting using the Super Signal West Pico Chemiluminescence System (Pierce). The results of several immunoblots were quantitatively analyzed using an LAS-3000 mini (FUJIFILM, Tokyo, Japan).

Supernatants containing equal amounts of protein (2 mg) were incubated with anti-IRS-1 and anti-IRS-2 antibodies (5 μg each) and then with 100 μl of protein A- and G-Sepharose. These immunoprecipitates and cell lysates were boiled in Laemmli sample buffer containing 100 mmol/liter dithiothreitol, electrophoresed, and immunoblotted with anti-IRS-1, anti-IRS-2, anti-p85 (phosphatidylinositol-3-kinase), anti-Pin1, phospho-Akt (Thr-308 and Ser-473), or 4G10 antibody. The bands were quantitatively analyzed using the LAS-3000 mini.

Preparation of Baculovirus-produced Recombinant Proteins—Full-length coding regions of human Pin1, GFP-tagged Pin1, IRS-1, and DsRed-tagged full-length and deletion mutants of IRS-1 were subcloned into pBacPAK9 transfer vector (Clontech, Mountain View, CA), and baculoviruses were prepared according to the manufacturer’s instructions. For protein production, Sf9 cells were infected with these baculoviruses and grown for 48 h.
Preparation of Glutathione S-transferase (GST)-Pin1 Fusion Protein—cDNAs encoding full-length human Pin1 and the WW and PPIase domains of Pin1 were subcloned into a pGEX-4T-1 vector (GE Healthcare), which was used to transform *Escherichia coli* JM105 (Promega, Madison, WI). Transformed cells were grown to an *A*<sub>600</sub> of 0.6 in LB medium supplemented with 0.1 mg/ml ampicillin and stimulated for 3 h with 1.0 mM isopropyl-β-D-thiogalactopyranoside. GST fusion proteins were isolated and purified by affinity chromatography on a glutathione-Sepharose 4B column (GE Healthcare). Glutathione was removed by dialysis against phosphate-buffered saline containing 10 mM dithiothreitol.

**RNA Interference**—For the knockdown of human Pin1, a validated Stealth<sup>TM</sup> RNAi of human Pin1 (5′-CGGCACAGCAGCAGUGUGGCAAAA-3′) was used. After RNAi and RNAiMAX in Opti-MEM had been mixed, they were introduced into HepG2 cells. The cell lysates were immunoprecipitated (IP) with anti-IRS-1 antibody followed by immunoblotting with anti-GFP antibody. C, IRS-1 was overexpressed with GFP or GFP-Pin1 in Sf9 cells. The cell lysates were immunoprecipitated with anti-IRS-1 antibody followed by immunoblotting with anti-GFP antibody. D, the mouse liver cell lysates were immunoprecipitated with anti-IRS-1, and the immunoprecipitates were immunoblotted with anti-Pin1 and anti-IRS-1. E, Pin1 structure. GST-Pin1, GST-Pin1 WW domain, and GST-Pin1 PPIase domain were prepared. With incubation, these GST-proteins were conjugated to beads and cell lysates from IRS-1 overexpressing Sf-9 cells. F, GST-Pin1, but not GST alone, bound to IRS-1 in vitro. G, GST-WW, but not the GST-PPIase domain, bound IRS-1. H, lysates of SF-9 cells overexpressing IRS-1 were treated with or without 40 units/ml alkaline phosphatase. Then the cell lysates were incubated with GST-WW domain and immunoprecipitated with anti-IRS-1 antibody. The immunoprecipitates were electrophoresed and immunoblotted with anti-GST antibody. I, HepG2 cells overexpressing IRS-1 or control LacZ were overexpressed with GFP or GFP-Pin1, then incubated with or without 1 μg/ml okadaic acid for 1 h. The cell lysates were immunoprecipitated with anti-IRS-1 antibody followed by immunoblotting with anti-GFP antibody.

**Intraperitoneal Glucose, Insulin, and Pyruvate Tolerance Tests**—Mice were fasted for 14 h followed by blood sampling and intraperitoneal injection of glucose (2 g/kg body wt), insulin (0.75 units/kg body wt), or pyruvate (2 g/kg body wt). Whole venous blood was obtained from the tail vein at the indicated times after the glucose load. Blood glucose was measured with a portable blood glucose monitor.

**In Vivo Insulin Stimulation**—In brief, mice were anesthetized with pentobarbital sodium. The portal vein was exposed, and 0.4 ml of normal saline (0.9% NaCl) with or without insulin (25 milliunits/g of body wt) was injected. Livers were removed 30 s later, hind limb skeletal muscles 90 s thereafter, and immediately homogenized with a Polytron homogenizer in 6 volumes of solubilization buffer. Both extracts were centrifuged at 15,000 g for 30 min at 4 °C, and the supernatants were used as samples for immunoprecipitation and immunoblotting.

**Glucose Uptake in Isolated Skeletal Muscle**—Mice were anesthetized, and soleus muscles were dissected out and rapidly cut into 2–3-mg strips. Muscle strips were incubated in a shaking water bath at 35 °C for 60 min in a 20-ml flask containing 2.0 ml Krebs-Henseleit bicarbonate buffer supplemented with 8 mM glucose, 32 mM mannitol, and 0.1% bovine serum albumin.
(BSA) (radioimmunoassay grade). Flasks were gassed continuously with 95% O2, 5%CO2 throughout the experiment. The muscles were then incubated for 20 min in oxygenated KRB buffer in the presence or absence of human insulin (2 milli-units/ml) and then incubated for 20 min at 29 °C in 1.5 ml of KRB buffer containing 8 mM 2-deoxy-D-[1,2-3H(N)]glucose (2.25 mCi/ml), 32 mM [14C]mannitol (0.3 mCi/ml), 2 mM sodium pyruvate, and 0.1% BSA. After the incubation, muscles were rapidly blotted, weighed, and solubilized with 1 ml of Soluene 350 (PerkinElmer Life Sciences). The samples were counted in a liquid scintillation counter. 2-Deoxy-[3H]glucose uptake rates were corrected for extracellular trapping using [14C]mannitol counts.

Quantitative Real-time Reverse Transcription-PCR—Total RNA was extracted from 3T3-L1 adipocytes or mouse liver and epididymal adipose tissue using Sepasol reagent (Nakalai Tesche, Kyoto, Japan). First-strand cDNAs were synthesized using PrimeScript reverse transcriptase with oligo(dT). Real-time PCR was performed using SYBR Green PCR master mix (Invitrogen) on an ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA). The primers were designed as follows: SREBP1 forward: GGAGCCATGGATTGACATATT; SREBP1 reverse, GGCCCGGGAAGTCACTG; SREBP2 forward, TAACCCCTTGACTTCCTTGCT; SREBP2 reverse, TGCTCTTAGCCTCATCCTCAA; ACC forward, TCTCTGGCTTACAGGATGGTTTG; ACC reverse, GAGTCTATTTTCTTCTGTCTCGACTTT; FAS forward, GCTGCAGAAACTTCAGGAAAT; FAS reverse, AGAGACGTTCATTGCTCCGTTAAG; SCD forward, GTCAGGGAACCTTCCA; SCD reverse, AGAGACGTTCATTGCTCCGTTAAG.

Statistical Analysis—Results are expressed as the means ± S.E., and significance was assessed using one way analysis of variance unless otherwise indicated.
**RESULTS**

*Increased Pin1 Expression in Mouse Liver, Muscle, and Fat Tissue with High-fat Diet Feeding*—We previously reported that Pin1 protein is increased in the fed state (19). In this study we speculated that Pin1 expression might be regulated by altered nutrient conditions and examined Pin1 expression alteration in mice fed a HFD. As shown in Fig. 1A, HFD feeding markedly increased Pin1 protein in liver, muscle, and epididymal fat tissue. Pin1 amounts in other tissues such as the brain were not significantly altered (supplemental Fig. 1).

*Enhancing Effect of Pin1 on Insulin Signaling*—Because Pin1 expression was affected by nutrient conditions, we examined the possible involvement of Pin1 in glucose and lipid metabolism regulation. First, to elucidate the effect of Pin1 on insulin signaling, HA-tagged Pin1 was overexpressed in HepG2 cells (Fig. 1B and supplemental Fig. 2A). The overexpressed Pin1 amount was ~5-fold that of endogenous Pin1. In this state, insulin-induced IRS-1 phosphorylation and p85 association with IRS-1 and Akt phosphorylation were all markedly enhanced, whereas IRS-1 and Akt protein amounts were unchanged. Pin1 gene suppression using siRNA attenuated the possible involvement of Pin1 in glucose and lipid metabolism regulation. First, to elucidate the effect of Pin1 on insulin signaling, HA-tagged Pin1 was overexpressed in HepG2 cells (Fig. 1B and supplemental Fig. 2A). The overexpressed Pin1 amount was ~5-fold that of endogenous Pin1. In this state, insulin-induced IRS-1 phosphorylation and p85 association with IRS-1 and Akt phosphorylation were all markedly enhanced, whereas IRS-1 and Akt protein amounts were unchanged. Pin1 gene suppression using siRNA attenuated these effects (Fig. 1C and supplemental Fig. 2B). Similar data were obtained using the Pin1-specific inhibitor Juglone, which has no effects on the activities of other prolyl isomerases, such as FKBP (FK506-binding protein) and cyclophilin A (21) (Fig. 1D and supplemental Fig. 2C). In addition, overexpression of the inactive mutant of Pin1 (R68A/R69A), in which Arg-68 and Arg-69 are replaced by Ala, failed to enhance insulin signaling (Fig. 1E and supplemental Fig. 2D). Thus, Pin1 expression level and activity regulate the efficiency of insulin-induced IRS-1 phosphorylation.

*Association of Pin1 with IRS-1*—Because Pin1 markedly enhanced insulin-induced IRS-1 phosphorylation, we considered a direct association of Pin1 with IRS-1. First, we used an MEF-tagged purification system, i.e. IRS-1 fused with N-terminal triple tags consisting of an myc tag, tobacco etch virus protease cleavage sequence, and FLAG tag overexpressed in mouse liver. Sequential affinity purification was performed using three steps; myc tag antibody immunoprecipitation, elution by tobacco etch virus protease digestion, and finally, FLAG tag antibody immunoprecipitation. Purified IRS-1 containing complexes were electrophoresed and then silver-stained, which demonstrated bait proteins of IRS-1 and many others including 14-3-3 proteins. Immunoblotting using Pin1 antibody indicated the presence of Pin1 in IRS-1 complexes (Fig. 2A). To confirm the association between IRS-1 and Pin1, IRS-1 and either GFP-Pin1 or GFP was co-overexpressed in HepG2 or Sf-9 cells. As shown in Fig. 2, B and C, GFP-Pin1, but not GFP alone, was detected in IRS-1 immunoprecipitates. Furthermore, Pin1 was detected in immunoprecipitates with anti-IRS-1 antibody, but not control IgG, from mouse liver (Fig. 2D). Thus, the association between IRS-1 and Pin1 is physiological.

To identify the Pin1 domain responsible for the association with IRS-1, GST-Pin1, the GST-Pin1 WW domain, and the GST-Pin1 PPlase domain were prepared (Fig. 2E). These GST proteins were conjugated to beads and incubated with cell lysates from IRS-1-overexpressing Sf-9 cells. GST-Pin1, but not GST alone, bound to IRS-1 in vitro (Fig. 2F). This pulldown system experiment revealed the GST-WW domain, but not that of GST-PPlase, to bind IRS-1 (Fig. 2G). In addition, treating IRS-1 with alkaline phosphatase completely abolished the association with Pin1 (Fig. 2H), whereas okadaic acid treatment significantly increased this association (Fig. 2I), suggesting involvement of serine and/or threonine phosphorylation in IRS-1.

Subsequently, six DsRed-tagged IRS-1 deletion (N termini) mutants (Fig. 3A) and GFP-tagged Pin1 were co-overexpressed in Sf-9 cells. As shown in Fig. 3B, the IRS-1 deletion mutant 3 containing amino acids 359–491 was immunoprecipitated with GFP-tagged Pin1. There are four serine-proline motifs in this portion (Fig. 3C). Each of these serine residues was replaced with alanine, and the mutant not associating with Pin1 was examined. As shown in Fig. 3D, IRS-1 with serine 434 replaced by alanine did not bind Pin1, indicating that the association between IRS-1 and Pin1 is mediated via the phosphoserine 434-containing motif in IRS-1 and the WW domain in Pin1. Ser-434 is in the SAIN (Shc and IRS-1 NPXY binding) domain, which...
Pin1 Enhances Insulin Actions and Adipogenesis

has been suggested to be involved in the association with the activated insulin receptor (22, 23). IRS-1 contains many serine/threonine residues that are heavily phosphorylated even under basal conditions, and Ser-434 is probably one such residue.

Furthermore, to test whether or not enhanced IRS-1 phosphorylation is really mediated by direct association between IRS-1 and Pin1, insulin-induced phosphorylation levels of IRS-1 were compared between immunoprecipitation with IRS-1 antibody versus anti-Pin1 antibody using HepG2 cells. There was much less IRS-1 in the anti-Pin1 antibody immunoprecipitate than in the anti-IRS-1 antibody immunoprecipitate, whereas insulin-induced IRS-1 phosphorylation was far greater with anti-Pin1 antibody immunoprecipitated IRS-1 (Fig. 3E). The tyrosine phosphorylation level/IRS-1 protein ratio was extremely high in the anti-Pin1 antibody immunoprecipitate as compared with the whole IRS-1 ratio. In addition, the effects of Pin1 on insulin-induced phosphorylations of S434A-mutated IRS-1 unable to associate with Pin1 as well as on IRS-2 were examined (Fig. 3F). FLAG-tagged wild-type, S434A IRS-1, or FLAG-tagged IRS-2 were co-overexpressed with Pin1 or LacZ in the HepG2 cells. The insulin-induced tyrosine phosphorylation of S434A IRS-1 was unaffected by Pin1 overexpression, whereas that of wild-type IRS-1 was markedly enhanced (Fig. 3F). It is noteworthy that IRS-2 phosphorylation is not significantly altered by Pin1. The phosphorylation of endogenous IRS-2 was also unaffected by Pin1 overexpression, although IRS-2 binds to Pin1 when overexpressed in HepG2 cells (supplemental Fig. 3). Our observations suggest that association of Pin1 with IRS-1 markedly enhances insulin-induced IRS-1 phosphorylation and its downstream signaling.

Insulin Resistance and Glucose Intolerance in Pin1 KO Mice—To elucidate the in vivo role of Pin1 in metabolism, the insulin signaling and sensitivity of Pin1 KO mice (20) were investigated. Insulin signaling was investigated first. Injecting insulin via the portal vein revealed insulin-induced IRS-1 tyrosine phosphorylation, the association of p85 with IRS-1 and Akt phosphorylation weaker in Pin1 KO liver and muscle than in those of wild-type mice (Fig. 4A and supplemental Fig. 4). Glucose and insulin tolerance tests demonstrated the insulin resistance of Pin1 KO mice (Fig. 4, C and D), whereas fasting serum insulin concentrations did not differ (Fig. 4B). The insulin-induced glucose uptake into isolated soleus muscle was also decreased in Pin1 KO mice as compared with controls, indicating muscle insulin resistance (Fig. 4E). The pyruvate tolerance test showed higher blood glucose concentrations in Pin1 KO mice, suggesting hepatic insulin resistance in these mice (Fig. 4F). Thus, in Pin1 KO mice, IRS-1 phosphorylation and downstream events are attenuated, and insulin resistance is present in both liver and muscle.

Hepatic Pin1 Overexpression Improves Insulin Resistance in ob/ob Mice—Interestingly, Pin1 expression was not altered in ob/ob mice as compared with lean controls. The reason is unclear, but we speculate that lack of a Pin1 expression response would exacerbate lipid and glucose metabolism abnormalities in ob/ob mice. We examined whether Pin1 overexpression might improve insulin resistance in ob/ob mice. Adenovirus for expressing Pin1 was injected intravenously. Adenovirus-mediated gene expression is reportedly limited to the liver (24) if adenovirus is injected into the bloodstream. Indeed, 72 h after injection, the amount of Pin1 was increased in the liver but not in muscle or adipose tissue (Fig. 5A and supplemental Fig. 5). In ob/ob mice, insulin-induced tyrosine phosphorylations of IRS-1 and IRS-2 and phosphatidylinositol 3-kinase/Akt activations were markedly impaired as...
reported previously (25) (Fig. 5, D–G). Pin1 overexpression normalized the decreased insulin-induced IRS-1, but not IRS-2, phosphorylation (Fig. 5, D and E). Hepatic Akt phosphorylations were also restored by Pin1 overexpression (Fig. 5, F and G). As reflected by improved insulin-signaling, glucose tolerance improved, i.e. fasting glucose concentrations (Fig. 5B) and expression levels of PEPCK and glucose-6-phosphatase were normalized (supplemental Fig. 6). The insulin tolerance test response was also improved (Fig. 5C). Thus, Pin1 overexpression improves insulin sensitivity in ob/ob mice.

Critical Role of Pin1 in Adipose Differentiation—Given the known role of insulin in adipose differentiation (26) and the increased Pin1 expression in WAT with HFD feeding, we speculated that Pin1 plays a critical role in diet-induced adipogenesis. First, Pin1 expression was shown to be up-regulated in 3T3-L1 cells during adipose differentiation (Fig. 6A). Then, the effect of Pin1 gene silencing using siRNA on adipose differentiation of 3T3-L1 adipocytes or human preadipocytes was examined (Fig. 6, B and C, and supplemental Fig. 7). Adipose differentiation of these cells was markedly impaired with suppressed inductions of PPARγ, c/EBPα, and C/EBPβ, known as master regulator genes of adipose differentiation (27–29) (Fig. 6D). In addition, expression of PPARγ protein, a marker of mature adipocytes, was reduced by Pin1 knockdown (Fig. 6C). Compensatory overexpression of PPARγ overcomes the suppressive effect of Pin1 siRNA on adipose differentiation (Fig. 6C).

Next, the adipose tissue of Pin1 KO mice was investigated. In normal mouse epididymal adipose tissue, PPARγ, c/EBPα, and CEBP/β as well as SREBP1, SREBP2, acetyl-CoA carboxylase, fatty acid synthase, and stearoyl-CoA-desaturase were markedly up-regulated by HFD feeding, which contributed to the enlargement of adipose tissues. In contrast, in Pin1 KO mouse adipose tissues, these increased gene expressions were significantly suppressed (Fig. 7, A and B), thereby markedly suppressing adipose tissue enlargement and weight gain on the HFD (Fig. 7, C and D). Thus, we concluded that Pin1 is a key regulator of diet-induced adipogene-
Pin1 Enhances Insulin Actions and Adipogenesis

As Pin1 KO mice were clearly resistant to HFD-induced obesity.

DISCUSSION

Pin1 amounts increased according to nutrient state, as shown by marked elevation on a high-fat as compared with a normal diet. The Pin1 level was also higher in the fed than in the fasted state (19). Whereas previous studies have shown that Pin1 expression generally correlates with cell proliferative potential in normal tissues (7, 12) and is further up-regulated in many human cancers (30, 31), our findings are the first suggesting a relationship between Pin1 protein and nutrient conditions.

We also demonstrated that Pin1 is a positive regulator of insulin signaling via enhanced insulin-induced IRS-1 phosphorylation, based on a data series obtained using in vitro and in vivo overexpression of Pin1, gene silencing, a specific inhibitor, and Pin1 KO mice. The principal insulin receptor substrates, IRS-protein family members such as IRS-1 and IRS-2, adaptor proteins from the activated insulin receptor, are tyrosine-phosphorylated and thereby activate phosphatidylinositol 3-kinase/Akt. Pin1 binds to the Ser-434-containing motif of IRS-1, which is in the SAIN domain, via its WW domain. Because the SAIN domain reportedly plays an important role in the association with the insulin receptor (21, 22), it is speculated that Pin1 modifies the conformation of the SAIN domain and thereby enhances IRS-1 tyrosine phosphorylation by the insulin receptor. Similar enhanced phosphorylation of signal transduction protein via association with Pin1 has been reported for STAT3 (32).

Regarding the downstream signaling from the insulin receptor, the phosphatidylinositol 3-kinase/Akt pathway activation is essential for almost all insulin-induced glucose and lipid metabolism activities, e.g. glucose uptake, glycogen synthesis, suppression of glucose output, and triglyceride synthesis. Thus, in the muscles of Pin1 KO mice showing impaired Akt activation, glucose incorporation into muscle with insulin stimulation was decreased.

Insulin-induced phosphatidylinositol 3-kinase/Akt activations also play a role in adipogenesis (25, 33). It was shown that Pin1-deficient preadipocytes clearly fail to differentiate into adipocytes. This suppression was accompanied by insufficient inductions of PPARγ, c/EBPα, and c/EBPβ. On the other hand, overexpression of PPARγ reversed the Pin1 siRNA-induced suppression of adipose differentiation. Although the molecular mechanisms underlying insulin-induced induction of adipogenic genes has yet to be fully elucidated, previous reports have shown the essential action of SREBPs for adipogenesis to probably be via regulation of its downstream PPARγ (34, 35). Indeed, in adipose tissue from Pin1 KO mice, SREBPs and downstream gene expressions were decreased. These observations indicate that, as a consequence of impaired adipose differentiation, Pin1 KO mice are resistant to HFD-induced obesity.

Based on our data series, we can speculate as to the physiological significance of Pin1 with respect to metabolic regula-

FIGURE 7. Pin1 KO mice are resistant to HFD-induced obesity. A, PPARγ, c/EBPα, and c/EBPβ mRNA levels in the adipose tissues of wild-type or Pin1 KO mice, fed a control diet or HFD for 4 weeks, were determined. B, SREBP1, SREBP2, ACC, FAS, and SCD mRNA levels in adipose tissues from wild-type or Pin1 KO mice, fed a control or HFD for 4 weeks, were determined by real-time PCR. C, weight gain after HFD feeding was compared between wild-type and Pin1 KO mice. D, the weights of the liver and adipose tissue were compared between wild-type and Pin1 KO mice, which had been fed either a control diet or HFD for 4 weeks. ACC, acetyl-CoA carboxylase; FAS, fatty acid synthase; SCD, stearoyl-CoA desaturase.
Intriguingly, Pin1 enhances the signal from IRS-1 but not that of IRS-2. Although IRS-2 bound to Pin1 when both were overexpressed in HepG2 cells (supplemental Fig. 3), no association and down-regulated by the aforementioned multiple kinases except Akt, leading to reduced insulin-induced IRS-1 tyrosine phosphorylations and thereby contributing to insulin resistance (38–43). Thus, the efficiency of IRS-1 tyrosine phosphorylations appear to be up-regulated by increased Pin1 association and down-regulated by the aforementioned multiple serine phosphorylations. We speculate that both phenomena take place under conditions of energy excess, but when prolonged, the latter down-regulating mechanism becomes dominant.

In conclusion, we have demonstrated the important role of Pin1 as a positive modulator of insulin signaling as well as an inducer of obesity. Thus, Pin1 might be regarded as somewhat of a double-edged sword in that it increases insulin sensitivity but also promotes obesity (Fig. 8). However, suppression of Pin1 activity specifically in adipocytes might be a novel preventive treatment for obesity. Otherwise, if hepatic lipid accumulation is not severe, agents increasing Pin1 expression or enzymatic activity, i.e., targeting Pin1, may hold promise for treating Type 2 diabetes mellitus by improving hepatic insulin sensitivity.

REFERENCES

1. Fischer, G., Wittmann-Liebold, B., Lang, K., Kiehaber, T., and Schmid, F. X. (1989) Nature 337, 476–478
2. Liu, J., Farmer, J. D., Jr., Lane, W. S., Friedman, J., Weissman, I., and Schreiber, S. L. (1991) Cell 66, 807–815
3. Choi, I., Chen, J., Schreiber, S. L., and Clardy, J. (1996) Science 273, 239–242
4. Loewith, R., Racinto, E., Wullischlager, S., Lorberge, A., Crespo, J. L., Bonenfant, D., Oppigluer, W., Jenoe, P., and Hall, M. N. (2002) Mol. Cell 10, 457–468
5. Schreiber, S. L. (1991) Science 251, 283–287
6. Kunz, J., and Hall, M. N. (1993) Trends Biochem. Sci. 18, 334–338
7. Lu, K. P., Hanes, S. D., and Hunter, T. (1996) Nature 380, 544–547
8. Wulf, G., Finn, G., Suzuki, F., and Lu, K. P. (2005) Nat. Cell Biol. 7, 435–441
9. Lu, K. P., and Zhou, X. Z. (2007) Nat. Rev. Mol. Cell Biol. 8, 904–916
10. Takahashi, K., Uchida, C., Shin, R. W., Shimazaki, K., and Uchida, T. (2008) Cell. Mol. Life Sci. 65, 359–375
11. Zhou, X. Z., Kops, O., Werner, A., Lu, P. J., Shen, M., Stoller, G., Kullertz, G., Stark, M., Fischer, G., and Lu, K. P. (2000) Mol. Cell 6, 873–883
12. Winkler, K. E., Swenson, K. I., Kornbluth, S., and Means, A. R. (2000) Science 287, 1644–1647
13. Zacchi, P., Gostissa, M., Uchida, T., Salvagno, C., Avolio, F., Volinia, S., Ronai, Z., Blandino, G., Schneider, C., and Del Sal, G. (2002) Nature 419, 853–857
14. Zheng, H., You, H., Zhou, X. Z., Murray, S. A., Uchida, T., Wulf, G., Gu, L., Tang, X., Lu, K. P., and Xiao, Z. (2002) Nature 419, 849–853
15. Lu, P. J., Wulf, G., Zhou, X. Z., Davies, P., and Lu, K. P. (1999) Nature 399, 784–788
16. Pastorino, L., Sun, A., Lu, P. J., Zhou, X. Z., Balastik, M., Finn, G., Wulf, G., Lim, J., Li, S. H., Li, X., Xia, W., Nicholson, L. K., and Lu, K. P. (2006) Science 312, 528–534
17. Liou, Y. C., Sun, A., Ryo, A., Zhou, X. Z., Yu, Z. X., Huang, H. K., Uchida, T., Bronson, R., Bing, G., Li, X., Hunter, T., and Lu, K. P. (2003) Nature 424, 556–561
18. Nakatsu, Y., Sakoda, H., Kushiyama, A., Ono, H., Fujishiro, M., Horike, N., Yokoda, M., Ohno, H., Tsuchiya, Y., Kamata, H., Tahara, H., Isobe, T., Nishimura, F., Katagiri, H., Oka, Y., Fukushima, T., Takahashi, S., Kurihara, H., Uchida, T., and Asano, T. (2010) J. Biol. Chem. 285, 33018–33027
19. Ichimura, T., Yamamura, H., Sasamoto, K., Tominaga, Y., Taoka, M., Kakiuchi, K., Shinkawa, T., Takahashi, N., Shimada, S., and Isobe, T. (2005) J. Biol. Chem. 280, 13187–13194
20. Fujimori, F., Takahashi, K., Uchida, C., and Uchida, T. (1999) Biochem. Biophys. Res. Commun. 265, 658–663
21. Hennig, L., Christner, C., Kipping, M., Schellbert, B., Rücknagel, K. P., Grabley, S., Küttler, G., and Fischer, G. (1998) Biochemistry 37, 5953–5960
22. Gustafsson, T. A., He, W., Craparo, A., Schaub, C. D., and O’Neill, T. J. (1995) Mol. Cell. Biol. 15, 2500–2508
23. Yenush, L., Makati, K. J., Smith-Hall, J., Ishibashi, O., Myers, M. G., Jr., and White, M. F. (1996) J. Biol. Chem. 271, 24300–24306
24. Ono, H., Shimano, H., Katagiri, H., Yahagi, N., Sakoda, H., Onishi, Y., Anai, M., Ogihara, T., Fukushima, M., Viana, A. Y., Fukushima, Y., Abe, M., Showa, N., Kikuchi, M., Yamada, N., Oka, Y., and Asano, T. (2003) Diabetes 52, 2905–2913
25. Kerouz, N. J., Hörsch, D., Pons, S., and Kahn, C. R. (1997) J. Clin. Invest. 100, 3164–3172
26. Nakae, J., Kitamura, T., Kitamura, Y., Biggs, W. H., 3rd, Arden, K. C., and Accili, D. (2003) Dev. Cell 4, 119–129
27. Umem, R. M., Friedman, A. D., and McKnight, S. L. (1991) Science 251, 288–292
Pin1 Enhances Insulin Actions and Adipogenesis

28. Tanaka, T., Yoshida, N., Kishimoto, T., and Akira, S. (1997) EMBO J. 16, 7432–7443
29. Spiegelman, B. M. (1998) Diabetes 47, 507–514
30. Ryo, A., Nakamura, M., Wulf, G., Liou, Y. C., and Lu, K. P. (2001) Nat. Cell Biol. 3, 793–801
31. Wulf, G. M., Ryo, A., Wulf, G. G., Lee, S. W., Niu, T., Petkova, V., and Lu, K. P. (2001) EMBO J. 20, 3459–3472
32. Lufei, C., Koh, T. H., Uchida, T., and Cao, X. (2007) Oncogene 26, 7656–7664
33. Rosen, E. D., and MacDougald, O. A. (2006) Nat. Rev. Mol. Cell Biol. 7, 885–896
34. Tontonoz, P., Kim, J. B., Graves, R. A., and Spiegelman, B. M. (1993) Mol. Cell Biol. 13, 4753–4759
35. Jiang, L., Wang, Q., Yu, Y., Zhao, F., Huang, P., Zeng, R., Qi, R. Z., Li, W., and Liu, Y. (2009) PLoS One 4, e6884
36. Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J., Ren, J. M., Previs, S., Zhang, Y., Bernal, D., Pons, S., Shulman, G. I., Bonner-Weir, S., and White, M. F. (1998) Nature 391, 900–904
37. Taniguchi, C. M., Emanuelli, B., and Kahn, C. R. (2006) Nat. Rev. Mol. Cell Biol. 7, 85–96
38. Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., and Spiegelman, B. M. (1996) Science 271, 665–668
39. Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., and Hotamisligil, G. S. (2002) Nature 420, 333–336
40. Pirola, L., Johnston, A. M., and Van Obberghen, E. (2004) Diabetologia 47, 170–184
41. Werner, E. D., Lee, J., Hansen, L., Yuan, M., and Shoelson, S. E. (2004) J. Biol. Chem. 279, 35298–35305
42. Ozcan, U., Yilmaz, E., Ozcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., and Hotamisligil, G. S. (2006) Science 313, 1137–1140
43. Morino, K., Neschen, S., Bilz, S., Sono, S., Tsirigotis, D., Reznick, R. M., Moore, I., Nagai, Y., Samuel, V., Sebastian, D., White, M., Philbrick, W., and Shulman, G. I. (2008) Diabetes 57, 2644–2651